Cargando…

Identification of ALK Gene Alterations in Urothelial Carcinoma

BACKGROUND: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinoma (UC) and its correlation with clinical or pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellmunt, Joaquim, Selvarajah, Shamini, Rodig, Scott, Salido, Marta, de Muga, Silvia, Costa, Irmgard, Bellosillo, Beatriz, Werner, Lillian, Mullane, Stephanie, Fay, André P., O'Brien, Robert, Barretina, Jordi, Minoche, André E., Signoretti, Sabina, Montagut, Clara, Himmelbauer, Heinz, Berman, David M., Kantoff, Philip, Choueiri, Toni K., Rosenberg, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118868/ https://www.ncbi.nlm.nih.gov/pubmed/25083769 http://dx.doi.org/10.1371/journal.pone.0103325

Ejemplares similares

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and Genome Analyzer systems
por: Minoche, André E, et al.
Publicado: (2011)

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
por: Bambury, Richard M, et al.
Publicado: (2015)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Upper tract urothelial carcinoma: a different disease entity in terms of management
por: Leow, Jeffrey J, et al.
Publicado: (2017)

p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing
por: Herrmann, Frank, et al.
Publicado: (2011)

Highly diverse chromoviruses of Beta vulgaris are classified by chromodomains and chromosomal integration
por: Weber, Beatrice, et al.
Publicado: (2013)

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2018)

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
por: Fay, André P, et al.
Publicado: (2015)

Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
por: Bowden, Michaela, et al.
Publicado: (2020)

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
por: Moreira, Raphael B., et al.
Publicado: (2017)

Exploiting single-molecule transcript sequencing for eukaryotic gene prediction
por: Minoche, André E., et al.
Publicado: (2015)

Genomes of the wild beets Beta patula and Beta vulgaris ssp. maritima
por: Rodríguez del Río, Álvaro, et al.
Publicado: (2019)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Editorial: Implementation of genomic and epigenomic innovation in clinical cancer diagnostics
por: Schenkel, Laila C., et al.
Publicado: (2023)

Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes
por: Georgescu, Ilinca, et al.
Publicado: (2016)

A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma
por: Ramírez de Olano, Amaya, et al.
Publicado: (2017)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer
por: Clavé, Sergi, et al.
Publicado: (2023)

Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4
por: Bellmunt, Joaquim
Publicado: (2018)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores
por: Patel, Palak G., et al.
Publicado: (2017)

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
por: Conde, Esther, et al.
Publicado: (2022)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
por: Casadevall, David, et al.
Publicado: (2016)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2013)

Erratum to: Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2016)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_udbv723jjo4cbb5vs1quqcloe1